Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30473406 | 0.87 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL18629790 | 0.85 | HSD17B10 (0.57) | HSD17B10SMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL29563708 | 0.85 | HSD17B10 (0.57) | HSD17B10SMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL29806041 | 0.82 | ABL1 (0.46) | HSD17B10SMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL30473427 | 0.81 | ABL1 (0.47) | HSD17B10SMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL29564053 | 0.81 | FFAR2 (0.47) | CXCR2RAB9APRKAA2ALDH1A1GRM5 | |
| SCHEMBL30899665 | 0.78 | HSD17B10 (0.56) | HSD17B10SMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL18629918 | 0.77 | NPC1 (0.56) | HSD17B10SMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL13434074 | 0.77 | RAB9A (0.53) | HSD17B10SMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL30071293 | 0.77 | NPC1 (0.56) | HSD17B10SMN1; SMN2NPC1RAB9ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11976057-B2 | MrgX2 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-05-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11976057-B2 | MrgX2 antagonists | MRGPRX2, MRGPRX1, MRGPRX4 | CXCR2 299/4885HSD17B10 2674/4885SMN1; SMN2 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.